A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
About Viatris Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges. Viatris’ executive management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders. The Company operates in more than 165 countries and territories with more than 30,000 employees.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 14.3B | 14.3B | 14.7B | 15.4B | 16.3B | 17.9B |
| Net Income | -3.5B | -3.5B | -634M | 94M | 1.9B | -1.3B |
| EPS | $-3.00 | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 |
| Free Cash Flow | 1.9B | 1.9B | 2.0B | 2.5B | 2.6B | 2.6B |
| ROIC | -6.8% | -11.5% | - | 1.2% | 2.9% | -0.1% |
| Gross Margin | 35.1% | 35.1% | 38.2% | 41.7% | 40.0% | 31.2% |
| Debt/Equity | 1.04 | 1.04 | 0.73 | 0.90 | 0.93 | 1.14 |
| Dividends/Share | $0.00 | $0.48 | $0.48 | $0.48 | $0.48 | $0.33 |
| Operating Income | -2.7B | -2.7B | - | 766M | 1.6B | -28M |
| Operating Margin | -18.6% | -18.6% | - | 5.0% | 9.9% | -0.2% |
| ROE | -22.4% | -20.2% | -3.3% | 0.5% | 9.2% | -5.8% |
| Shares Outstanding | 1,172M | 1,172M | 1,197M | 1,876M | 1,114M | 1,209M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 11.4B | 11.5B | 11.9B | 17.9B | 16.3B | 15.4B | 14.7B | 14.3B | 14.3B |
| Gross Margin | 35.0% | 33.9% | 31.8% | 31.2% | 40.0% | 41.7% | 38.2% | 35.1% | 35.1% |
| R&D | 705M | 640M | 555M | 751M | 662M | 805M | 809M | 966M | 966M |
| SG&A | 2.4B | 2.6B | 3.3B | 4.5B | 4.2B | 4.1B | 4.1B | 3.8B | 3.8B |
| EBIT | 906M | 716M | -211M | -28M | 1.6B | 766M | N/A | -2.7B | -2.7B |
| Op. Margin | 7.9% | 6.2% | -1.8% | -0.2% | 9.9% | 5.0% | N/A | -18.6% | -18.6% |
| Net Income | 353M | N/A | -670M | -1.3B | 1.9B | 94M | -634M | -3.5B | -3.5B |
| Net Margin | 3.1% | N/A | -5.6% | -7.1% | 11.7% | 0.6% | -4.3% | -24.6% | -24.6% |
| Non-Recurring | 0 | 105M | 51M | 51M | 1.9B | 340M | 321M | 2.9B | 2.9B |
| Returns on Capital | |||||||||
| ROIC | 56.4% | N/A | -0.7% | -0.1% | 2.9% | 1.2% | N/A | -11.5% | -6.8% |
| ROE | N/A | N/A | -2.9% | -5.8% | 9.2% | 0.5% | -3.3% | -20.2% | -22.4% |
| ROA | 21.9% | N/A | -1.4% | -2.2% | 3.6% | 0.2% | -1.5% | -8.9% | -9.5% |
| Cash Flow | |||||||||
| Op. Cash Flow | 2.3B | 1.8B | 1.2B | 3.0B | 3.0B | 2.9B | 2.3B | 2.3B | 2.3B |
| Free Cash Flow | 2.1B | 1.6B | 989M | 2.6B | 2.6B | 2.5B | 2.0B | 1.9B | 1.9B |
| Owner Earnings | 228M | -272M | -1.1B | -1.6B | -145M | -21M | -736M | -660M | -660M |
| CapEx | 252M | 213M | 243M | 457M | 406M | 377M | 326M | 379M | 379M |
| Maint. CapEx | 2.1B | 2.0B | 2.2B | 4.5B | 3.0B | 2.7B | 2.9B | 2.8B | 2.8B |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 2.1B | 2.0B | 2.2B | 4.5B | 3.0B | 2.7B | 2.9B | 2.8B | 2.8B |
| CapEx/OCF | 10.8% | 11.8% | 19.7% | 15.2% | 13.5% | 13.0% | 14.2% | 16.4% | 16.4% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 432M | 0 | 0 | 0 | 0 | 250M | 250M | 500M | 500M |
| Buyback Yield | 3.7% | N/A | N/A | N/A | N/A | 1.3% | 1.8% | 3.5% | 3.1% |
| Stock-Based Comp | 3.3M | 57M | 79M | 111M | 116M | 181M | 146M | 178M | 178M |
| Debt Repayment | 3.2B | 1.1B | 2.5B | 4.2B | 3.7B | 1.3B | 3.7B | 100K | 100K |
| Balance Sheet | |||||||||
| Net Debt | 2.1B | 12.5B | 25.3B | 22.6B | 18.2B | 17.4B | 12.6B | 13.7B | 15.0B |
| Cash & Equiv. | 388M | 476M | 844M | 701M | 1.3B | 992M | 735M | 1.3B | 1.3B |
| Long-Term Debt | 2.6B | 11.2B | 22.4B | 19.7B | 18.0B | 16.2B | 14.0B | 12.5B | 12.5B |
| Debt/Equity | N/A | N/A | 1.14 | 1.14 | 0.93 | 0.90 | 0.73 | 1.04 | 1.04 |
| Interest Coverage | 1.7 | 1.4 | -0.4 | -0.0 | 2.7 | 1.3 | N/A | -5.7 | -5.7 |
| Equity | N/A | 0 | 23.0B | 20.5B | 21.1B | 20.5B | 19.1B | 15.7B | 15.7B |
| Total Assets | 1.6B | 31.3B | 61.6B | 54.8B | 50.0B | 47.7B | 41.5B | 37.2B | 37.2B |
| Total Liabilities | N/A | 19.4B | 38.6B | 34.4B | 28.9B | 27.2B | 22.9B | 22.5B | 22.5B |
| Intangibles | N/A | 11.6B | 29.7B | 26.1B | 22.6B | 19.2B | 17.1B | 15.1B | 15.1B |
| Retained Earnings | N/A | 6.0B | 5.4B | 3.7B | 5.2B | 4.6B | 3.4B | -388M | -388M |
| Working Capital | N/A | 1.2B | 2.3B | 1.0B | 3.9B | 5.2B | 3.7B | 2.7B | 2.7B |
| Current Assets | N/A | 6.8B | 12.9B | 10.9B | 10.6B | 13.0B | 9.5B | 9.8B | 9.8B |
| Current Liabilities | N/A | 5.6B | 10.6B | 9.9B | 6.7B | 7.8B | 5.8B | 7.1B | 7.1B |
| Per Share Data | |||||||||
| EPS | 0.68 | 0.03 | -1.11 | -1.05 | 1.71 | 0.05 | -0.53 | -3.00 | -3.00 |
| Owner EPS | 0.44 | -2,724,000.00 | -1.76 | -1.32 | -0.13 | -0.01 | -0.62 | -0.56 | -0.56 |
| Book Value | N/A | 0.00 | 38.03 | 16.95 | 18.91 | 10.91 | 16.00 | 13.42 | 13.42 |
| Cash Flow/Share | 4.52 | 18,037,000.00 | 2.04 | 2.50 | 2.69 | 1.55 | 1.92 | 1.98 | -0.61 |
| Dividends/Share | N/A | N/A | N/A | 0.33 | 0.48 | 0.48 | 0.48 | 0.48 | 0.00 |
| Shares Out. | 518.4M | 0.0M | 603.5M | 1.2B | 1.1B | 1.9B | 1.2B | 1.2B | 1.2B |
| Valuation | |||||||||
| P/E Ratio | 32.8 | 537.3 | N/A | N/A | 5.6 | 198.4 | N/A | N/A | -4.6 |
| P/FCF | 5.5 | 0.0 | 8.9 | 5.4 | 4.1 | 7.4 | 7.2 | 7.5 | 8.4 |
| EV/EBIT | 15.1 | 17.1 | N/A | N/A | 17.7 | 46.6 | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 0.4 | 0.7 | 0.5 | 0.9 | 0.7 | 0.9 | 1.0 |
| Price/Sales | 1.4 | 0.0 | 0.7 | 0.8 | 0.6 | 1.1 | 0.9 | 0.8 | 1.1 |
| FCF Yield | 18.1% | 98669925.5% | 11.3% | 18.6% | 24.4% | 13.6% | 13.9% | 13.4% | 12.0% |
| Market Cap | 11.6B | 2K | 8.8B | 13.8B | 10.6B | 18.6B | 14.2B | 14.4B | 16.2B |
| Avg. Price | 31.06 | 18.27 | 13.82 | 12.04 | 9.47 | 9.05 | 10.92 | 9.61 | 13.83 |
| Year-End Price | 22.29 | 16.12 | 14.50 | 11.41 | 9.52 | 9.92 | 11.88 | 12.32 | 13.83 |
Viatris Inc passes 1 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 8.2x vs a median of 6.4x. The company's 5-year average gross margin is 37.2%. Total shareholder yield (dividends + buybacks) is 6.6%. At current prices, the estimated annualized return to fair value is -10.0%.
Viatris Inc (VTRS) has a 5-year average return on invested capital (ROIC) of -1.9%. This is below average and may indicate limited pricing power.
Viatris Inc (VTRS) has a market capitalization of $16.2B. It is classified as a large-cap stock.
Yes, Viatris Inc (VTRS) pays a dividend with a trailing twelve-month yield of 3.47%. The company also returns capital through share buybacks, with a buyback yield of 3.09%.
Viatris Inc (VTRS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Viatris Inc (VTRS) reported annual revenue of $14.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
Viatris Inc (VTRS) has a net profit margin of -24.6%. The company is currently unprofitable.
Viatris Inc (VTRS) generated $1.9 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Viatris Inc (VTRS) has a debt-to-equity ratio of 1.04. This indicates moderate leverage.
Viatris Inc (VTRS) reported earnings per share (EPS) of $-3.00 in its most recent fiscal year.
Viatris Inc (VTRS) has a return on equity (ROE) of -20.2%. A negative ROE may indicate losses or negative equity.
Viatris Inc (VTRS) has a 5-year average gross margin of 37.2%. This indicates decent pricing power.
The Ledger Terminal provides 8 years of financial data for Viatris Inc (VTRS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Viatris Inc (VTRS) has a book value per share of $13.42, based on its most recent annual SEC filing.